Several analysts have recently updated their ratings and price targets for Denali Therapeutics (NASDAQ: DNLI): 3/2/2023 – Denali Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $85.00 to $70.00. They now have an 'outperform' rating on the stock. 3/2/2023 – Denali Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. 3/1/2023 – Denali Therapeutics had its price target lowered by analysts at Morgan Stanley from $65.

https://www.dailypolitical.com/2023/03/06/analysts-recent-ratings-updates-for-denali-therapeutics-dnli.html

#dailypolitical